Treatment for the Rare Disease Congenital Hyperinsulinism

The U.S. Food and Drug Administration (FDA) has designated Hanmi Pharmaceutical's new biologic drug for the treatment of a rare disease as a Breakthrough Therapy.


Hanmi Pharmaceutical announced on the 5th that on the 3rd (local time), the FDA designated Epegeogeulrukagon (HM15136), a treatment for congenital hyperinsulinism (CHI), as a Breakthrough Therapy Designation (BTD). The FDA's BTD program grants various benefits to support expedited approval for drugs whose clinical data demonstrate the potential for substantial clinical improvement over existing therapies in the treatment of serious diseases.

On the 3rd (local time), the U.S. Food and Drug Administration (FDA) designated Hanmi Pharmaceutical's congenital hyperinsulinism (CHI) treatment Epegeogeullukagon (HM15136) as a Breakthrough Therapy Designation (BTD). Hanmi Pharmaceutical

On the 3rd (local time), the U.S. Food and Drug Administration (FDA) designated Hanmi Pharmaceutical's congenital hyperinsulinism (CHI) treatment Epegeogeullukagon (HM15136) as a Breakthrough Therapy Designation (BTD). Hanmi Pharmaceutical

View original image

A therapy designated as BTD receives intensive guidance and support from the FDA throughout development, from clinical trials through approval. During the marketing application process, a Rolling Review is allowed, under which portions of the application can be submitted and reviewed sequentially. The likelihood of qualifying for expedited review mechanisms, such as Priority Review, also increases. A Hanmi Pharmaceutical official said, "Through the BTD, we will continue close discussions with the FDA to efficiently design and conduct the phase 3 clinical trial."


Epegeogeulrukagon has already been designated as an orphan drug (ODD) for the treatment of congenital hyperinsulinism by the U.S. FDA, the European Medicines Agency (EMA), and the Korean Ministry of Food and Drug Safety. The U.S. FDA has also designated it as a Rare Pediatric Disease (RPD) treatment, and the EMA has additionally designated Epegeogeulrukagon as an orphan drug for the treatment of insulin autoimmune syndrome.


Congenital hyperinsulinism is a rare disease in which excessive secretion of insulin causes hypoglycemia. To date, there is no FDA-approved therapy that specifically lists congenital hyperinsulinism as an indication. Existing therapies approved for the purpose of controlling hypoglycemia caused by hyperinsulinism can be used only in certain genotypes and have drawbacks such as side effects including hirsutism.


Hanmi Pharmaceutical is developing Epegeogeulrukagon as the world's first once-weekly formulation. A global phase 2 clinical trial is currently underway, and the results are scheduled to be announced in the second half of this year.



Choi Inyoung, head of Hanmi Pharmaceutical's R&D Center, said, "The FDA's Breakthrough Therapy designation is an objective indicator that the FDA has highly evaluated not only the urgent need for commercialization but also the actual feasibility of development," adding, "We will concentrate all of the company's capabilities on achieving faster development so that we can bring great hope to patients suffering from this disease."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing